The most frequent site of ocular metastasis is the choroid. The occurrence of choroidal metastases has increased steadily due to the longer survival of metastatic patients and the improvement of diagnostic tools. Fundoscopy, ultrasonography, and fluorescein angiography are now complemented by indocyanine green angiography and optical coherence tomography. Choroidal tumor biopsy may also confirm the metastatic nature of the tumor and help to determine the site of the primary malignancy.
Introduction
The first case of choroidal metastasis (CM) was documented by Perls in 1872 (Perls, 1872) . Although CM have long been considered a rare entity, they are now known to be the most common intraocular malignancy (Albert et al., 1967b; Ferry and Font, 1974; Shields et al., 1997b) . The increasing survival of patients with metastases and better diagnostic tools may explain these findings, yet the incidence of CM is probably even higher than reported due to underdiagnosis among patients with poor general condition. Nonetheless, CM is the first sign of a systemic malignancy in up to a third of patients with cancer . Given the visual consequences, the ophthalmologist should play a key role for prompt and accurate diagnosis to begin the general work-up. The methods for CM diagnosis have improved over recent decades. Fundoscopy, ultrasonography (US), and fluorescein angiography are now complemented by indocyanine green angiography (ICGA), optical coherence tomography (OCT), and, more recently, spectral domain-OCT (SD-OCT). Histopathological diagnosis is also made possible by choroidal tumor biopsy that can confirm the nature of the tumor and help determine the site of the primary cancer. There is still debate as to the best way to treat patients with CM. As most patients have a limited life expectancy, complex treatments are generally not recommended. Ocular treatment in a patient with multiple metastases is considered a palliative measure, and, as such, aims to save vision and prevent the development of pain in order to improve quality of life. Fulfilling this objective provides a double challenge: on the one hand, the treatment should be easy to implement and should have a low risk of complication, and on the other hand it should be effective and improve or stabilize vision, which is essential for end-oflife well-being. However, recent advances in systemic therapies have significantly improved the survival of metastatic patients. Such patients may benefit from an effective and durable ocular treatment that will preserve vision throughout their prolonged survival.
The present review will focus on recent findings that have enhanced the clinical understanding and the management of CM.
Epidemiology of choroidal metastases

Prevalence of choroidal metastases
Until the 1970s there was a belief that metastatic tumors in the uveal tissue were relatively rare but it has since been shown in several studies that these are the most common uveal malignancy; they are even more frequent than primary uveal melanoma (Albert et al., 1967a; Bloch and Gartner, 1971; Ferry and Font, 1974; Shields et al., 1997b) .
The prevalence of intraocular metastases has been studied using two different methods: systematic post-mortem histopathological examination of ocular globes in cohorts of patients who died of cancer (Bloch and Gartner, 1971; Eliassi-Rad et al., 1996; Nelson et al., 1983) , and complete ophthalmologic examination in cohorts of patients diagnosed with cancer (Albert et al., 1967a; Barak et al., 2007; Kreusel et al., 2002; Mewis and Young, 1982; Su et al., 2008; Wiegel et al., 1998) . The prevalence of metastases estimated from post-mortem examination ranged from 4 to 10%. As expected, this was higher than the prevalence in patients living with cancer, which ranged from 2 to 7%, with the exception of Mewis et al. who reported a much higher prevalence that is likely to be related to the large proportion of symptomatic patients referred for examination (Table 1) (Mewis and Young, 1982) .
Primary neoplasms associated with choroidal metastases
The most frequent primary tumor site of CM is breast, which is found in 40-53% of cases (Demirci et al., 2003; Ferry and Font, 1974; Freedman and Folk, 1987; Merrill et al., 1991; Shields et al., 1997b) . The second most frequent is lung, which is found in 20-29% of cases (Ferry and Font, 1974; Freedman and Folk, 1987; Shah et al., 2014; Shields et al., 1997b) . Less frequent primary tumors include carcinomas of the gastrointestinal tract (4%), prostate (2%), kidney (2%), and skin (2%) Dieckert and Berger, 1982; Ferry and Font, 1974; Harbour et al., 1994; Shields et al., 1997b) . There are also reports of tumors originating from the salivary glands (Gutmann et al., 1986; Shields et al., 2000a) , thyroid (Avram et al., 2004; Besic and Luznik, 2013) , testes (Ferry and Font, 1974; Freedman and Folk, 1987) , female genital organs (Krohn-Hansen et al., 1999) , and urothelial tract (Nabi et al., 2002) . Ocular metastases from neuroendocrine tumors are rare, but given the scarcity of this cancer, ocular spread should be investigated (Eagle et al., 2000; Isidori et al., 2002; Schalenbourg et al., 2011) . Sarcomas even more rarely metastasize to the choroid (Anderson et al., 2011; Feinstein et al., 2014; Jampol et al., 1973) (Fig. 1) .
CM may also follow cutaneous, mucosal, or choroidal melanomas (de Bustros et al., 1985; Font et al., 1967; Ramaesh et al., 1999) . These metastases account for approximately 2-3% of ocular metastatic disease but their prevalence is probably underestimated. Post-mortem studies found ocular involvement in a third of patients who died from metastatic cutaneous melanoma (Fishman et al., 1976) . In a series of 68 eyes of patients with cutaneous melanoma metastatic to the eye, Ramaesh et al. found 40% choroidal and 35% ciliary/iris involvement; moreover, 49% of patients had a vitreoretinal involvement, and 13% an anterior chamber involvement (Ramaesh et al., 1999) .
Most patients have known systemic cancer at the time of CM diagnosis, but in 8-30% of cases the diagnosis of CM precedes that of systemic cancer. In these cases, a complete workup revealed lung cancer in 35-59% of cases and breast cancer in 7-15% of cases (Amer et al., 2004; Konstantinidis et al., 2014; Shields et al., 1997b) . These findings suggest that the presence of uveal metastases in a patient without Table 1 Occurrence of choroidal metastases in patients with known cancer.
Authors
Primary cancer
Number of patients Number of patients with choroidal metastases Albert et al. (1967a) All cancers 213 5 (2.3%) 10 patients with ocular metastases overall Mewis and Young (1982) Breast 250 67 (26.8%) Wiegel et al. (1998) Breast 120 6 (5.0%) Kreusel et al. (2002) Lung 84 6 (7.1%) Barak et al. (2007) Breast and Lung 169 patients (77 breast, 92 Lung) 2 (1.2%) Only among patients with breast cancer Su et al. (2008) Lung 8484 11 (< 1%)
Fig. 1.
Most common primary source of choroidal metastases.
T. Mathis et al. Progress in Retinal and Eye Research 68 (2019) history of cancer should prompt a thorough investigation for lung and breast cancer. However, in the study reported by Shields et al., the primary site was not found after initial general work-up in 51% of such patients . Table 2 presents a comparison between CM from breast and lung cancer. It appears that clinical and epidemiological features could help identify the type of primary neoplasm. The bilateral and the multifocal involvement are more suggestive of breast cancer than of lung cancer. In cases of breast cancer, almost all are women, and diagnosis of CM precedes that of primary tumor in about 10% of patients. In cases of lung cancer, the majority of cases occur in men, and the primary tumor is known in about a half of cases (Demirci et al., 2003; Shah et al., 2014) . The mean interval between diagnosis of primary neoplasm and CM is shorter for lung carcinomas than for breast cancers (Demirci et al., 2003; Freedman and Folk, 1987; Shah et al., 2014) , as is the mean survival following CM diagnosis (Demirci et al., 2003; Freedman and Folk, 1987; Shah et al., 2014) . Most studies reporting CM of lung cancer did not differentiate between non-small cell and small cell carcinomas, although it is well known that small cell lung carcinoma preferentially affects younger patients and leads to worse prognosis than non-small cell carcinoma.
Other ocular localizations of metastases
Uveal metastases involve the choroid in 88-89% of cases, and less frequently the iris (9%) or ciliary body (2%); isolated involvement of the retina, optic disc, or vitreous is exceptional Shields et al., 1997b) .
In iris metastases, breast cancer origin is less frequent than in choroidal involvement (Demirci et al., 2003; Konstantinidis et al., 2014; Shah et al., 2014) . Iris involvement is usually unilateral, with a synchronous choroidal localization in a third of cases (J. A. Shields et al., 1995c) . Ciliary body involvement is rare, and may be secondary to a choroidal localization. Optic disc metastases represent less than 5% of intraocular metastases and are in continuity with a juxtapapillary choroidal lesion in about 75% of cases. The other 25% are isolated optic nerve lesions in the pre-and retrolaminar portions (Shields et al., 2000b) . Breast and pulmonary carcinomas are the most common causes of optic nerve metastases and their prognosis is poor; mean survival is approximately one year (Shields et al., 2000b) . Retinal metastases are rare and only a few cases have been described in the literature (Leys et al., 1990; Shields et al., 1997b; Spraul et al., 1995) . Vitreous metastases are even more rare, and may occur via seeding from the retina secondary to inflammation of the internal limiting membrane (Young et al., 1979) . Overall, the incidence of extra-choroidal involvement is low, and this may be explained by a choroidal preference of metastatic cells.
Physiopathology of the metastasic mechanism
Advances in membrane cell staining have led to a better understanding of the mechanisms involved in cancer metastasis (Kuhn et al., 2005; Paris and Sesboüé, 2004) , which consist of multiple steps that begin when tumor cells leave the extracellular matrix and invade the surrounding tissue. These migrate towards the blood supply and pass through thin-walled vessels to reach the systemic circulation. Tumor cells then form small aggregates that can be retained in distal microvascular beds and some of them may access the underlying tissue and interact with stromal cells which promote their growth (Langley and Fidler, 2011) . With increasing metabolic needs associated with unrestrained cell division, tumor cells secrete proangiogenic factors that induce adjacent endothelial cells to form new vascular networks. The whole metastatic process is nonetheless highly inefficient, with less than 0.01% of circulating tumor cells eventually leading to secondary tumor growths (Fidler, 1970) . Many studies have investigated potential limiting steps in this process and it appears that the most difficult is initiating cell growth in secondary organs (Chambers et al., 1995) . After exiting from the cell cycle, some tumor cells remain dormant in secondary organs (Barkan et al., 2010) , while others are incapable of triggering the angiogenic switch necessary for tumor expansion (Hedley and Chambers, 2009 ). This complex series of interactions between metastatic cells and their target organ will determine whether metastatic growth occurs in a given organ.
There are two major theories attempting to explain the preferential target organ, and these are detailed below.
Anatomical-mechanical mechanism
The first mechanism suggests an important role of vascular and lymphatic drainage from the site of the primary tumor (Ewing, 1928) . According to this hypothesis, tumor cells follow the circulatory drainage from the primary tumor and are retained non-specifically in the capillary bed of the first organ encountered. This is supported by the higher frequency of metastases in the first organ "downstream" of the primary tumor. The typical example is liver metastases of colorectal tumors that drain through the portal vein directly into the liver (Bierman et al., 1951) .
More specifically for CM, Duke-Elder and Perkins were the first to hypothesize that the short posterior ciliary arteries are the preferential route for embolic cells (Duke-Elder and Perkins, 1966) . This would explain why the choroid is the most frequently involved ocular site. Ferry and Font then speculated that the abundant supply of posterior ciliary arteries to the posterior choroid is one of the causes of the predominant post-equatorial location of metastases in the choroid (Ferry and Font, 1974) . This may explain the greater involvement of the choroid than the iris or ciliary body . Moreover, the metastatic cells do not have to cross the blood-retinal barrier to reach the choroid, potentially explaining the low rate of retinal involvement.
The laterality of CM has been discussed by several authors. In some studies, the left eye was more frequently involved (De Ocampo and Espiritu, 1961; Jensen, 1970; Singh et al., 2012) , and it has been proposed that this is related to the more direct path to the eye provided by the left common carotid that originates from the aorta. However, other studies found CM more frequently in the right eye (Amer et al., 2004; Goldberg et al., 1990; Kreusel et al., 2008 ) and large studies found no particular difference in laterality (Freedman and Folk, 1987; Konstantinidis et al., 2014; Shields et al., 1997b) .
Seed and soil mechanism
It is well known that breast metastases have particular organ preference. In the "seed and soil" theory proposed by Paget, metastatic growth does not occur randomly but is due to appropriate tumor cells Table 2 Comparison between choroidal metastases from breast (n = 623 patients) and lung cancer (n = 327 patients) (Demirci et al., 2003; Freedman and Folk, 1987; Konstantinidis et al., 2014; Mewis and Young, 1982; Shah et al., 2014; Shields et al., 1997b) .
("seed") needing suitable microenvironment ("soil") to grow (Paget, 1889) . This theory, partially based on the work of Fuchs on emboli from uveal melanoma (Fuchs, 1882) , suggests that metastases grow only if the seed is implanted in its suitable soil. Paget proposes that the microenvironment plays the most important role in regulating the growth of metastases. This concept is supported by multiple experimental studies in which metastatic cells were grafted into different target organs, showing good correlation between in vitro and in vivo organ preference (Auerbach et al., 1987; Greene and Harvey, 1964; Kinsey, 1960; Schackert and Fidler, 1988) .
Blood flow through a given organ is an important factor in the "seeding" process, allowing a greater number of cells to be delivered in a given time, or more efficient "seeding". Weiss proposed to quantify and compare the ability of different organs to promote metastatic growth depending on their blood flow. He developed the metastatic efficiency index (MEI), which is defined as the ratio between incidence of metastases in an organ and the organ's blood flow (Weiss, 1992) :
Thus, high MEI indicates "fertile" seed and soil interactions, whereas low MEI indicates "hostile" seed and soil interactions. If the frequency of metastases in an organ is high compared to its blood flow (high MEI), there may be strong seed and soil interaction, indicating a good match between tumor type and target organ. On the other hand, a highly-vascularized organ with a low frequency of metastases (low MEI) could be explained by weak seed and soil interaction. (Weiss, 1992) .
The choroid is one of the most vascularized tissues in the body, and although only 0.013% of cardiac output is directed to the eye (approximately 0.6-0.8 ml per minute), 80-85% of this flow is dedicated to the choroid, (Alm et al., 1973; Langham and Kramer, 1990) . According to Weiss, the choroid has the highest MEI of any site in the body with a choroidal tissue involvement in 8-10% of metastatic cases (McCartney, 1993; Weiss, 1993) . Comparison of the MEI value of the choroid for primary breast cancer (MEI = 13.5) with that of the adrenal glands (MEI = 0.347) is particularly interesting because the adrenal glands were previously considered to be the preferential target site for metastatic breast cancer; the same was found for primary lung and colorectal carcinomas (Weiss, 1993) . This high affinity for the choroid may be due to specific vessel wall architecture, or interactions between adhesion molecules on the surface of the cancer cells and endothelial ligand sites (Albert et al., 1967b; McCartney, 1993) . However, the "seed and soil" and the anatomical-mechanical hypothesis are not mutually exclusive, and it is possible that one or both models could be at play.
Wound-oncogene-wound-healing model
A recent hypothesis, termed wound-oncogene-wound-healing (WOWH), proposes another type of metastasis which does not require cell migration (Meng et al., 2012) . According to this theory, cancer is the result of an attempt of the body to heal a wound. At the site of the "abnormal" wound, oncogenes are activated, and various "wound" molecules are produced; these circulate through the body and are able to activate oncogenes in distant tissues. The cells with activated oncogenes will transform and overproliferate, leading to a metastatic foci on the remote site without primary cancer cell migration.
According to the WOWH mechanism, oncogenes are physiologically activated in some tissues, and the presence of circulatory wound molecules could stimulate this activity. This could explain why cancer cells are found in the brain despite the presence of the blood-brain barrier, or why there is often no trail of cells on the path from the primary site to the distant metastatic sites (Nathoo et al., 2005) (Fig. 2) .
Diagnosis of choroidal metastases
Clinical findings
Symptoms
Blurred vision occurs in 55-70% of eyes and is often related to macular or juxtapapillary retinal involvement or due to foveal exudative retinal detachment Shields et al., 1997b) . Phosphenes and floaters are less frequent than in choroidal melanoma (12% of cases of CM), as are visual field defects (15.5.% of cases of CM) Shields et al., 1997b) . Pain, outside the context of uveitis or glaucoma, is more frequently reported by patients with CM from lung cancer (12%) than breast cancer (6%) (Demirci et al., 2003; Konstantinidis et al., 2014; Shah et al., 2014) . There remains 15-20% of patients who are non-symptomatic in which metastases are discovered by a routine exam or during a systemic evaluation of a generalized cancer (Demirci et al., 2003; Konstantinidis et al., 2014; Konstantinidis and Damato, 2017) .
Clinical examination
CM generally appear as creamy white or pale yellow masses associated with subretinal fluid (SRF). Their appearance can be either flat or plateau shaped, but there are rare descriptions of CM that are mushroom shaped as result of Bruch's membrane rupture ). An orange color can be seen in metastases that originate from carcinoid tumors (Harbour et al., 1994) , renal cell (Freedman and Folk, 1987; Haimovici et al., 1997; Kindermann et al., 1981) , or thyroid carcinomas (Ferry and Font, 1974; Freedman and Folk, 1987; Harbour et al., 1994) (Fig. 3) . A dark-brown color can be seen in case of CM from melanoma (cutaneous, mucosal, or uveal), which can appear clinically Oncogenes that have physiological activity in some tissues can be stimulated by persistently circulatory wound molecules derived from the cancer wounds. The cells with activated oncogenes will transform and over-proliferate, leading to another cancer mass on the remote site without primary cancer cell migration (adapted from Meng et al. (2012) ). similar to primary choroidal melanoma (de Bustros et al., 1985; Font et al., 1967; Ramaesh et al., 1999) although they are more frequently multifocal with a faster growth pattern. Some CM have orange lipofuscin pigment at the surface, mimicking choroidal melanoma, or dark pigment patches resembling "leopard skin" (Fig. 4) .
The most common associated feature of CM is SRF, which is observed in 28-73% of patients Shields et al., 1997b) . This fluid, located between photoreceptor outer segments and retinal pigment epithelium (RPE), is preferentially perilesional or positional.
Bilateral (15-50% of cases), multifocal (mean number of foci ranges from 1.4 to 1.6), and diffuse forms are more commonly associated with breast cancer (Demirci et al., 2003; Jardel et al., 2014; Konstantinidis et al., 2014; Maor et al., 1977; Mewis and Young, 1982; Röttinger et al., 1976; Rudoler et al., 1997b; Shields et al., 1997b) (Fig. 5) . Most CM are posterior to the equator (80%) and it has been reported that up to 40% are located in the macular region . The mean size of CM is 9 mm at the base and 3 mm in thickness, although thicker tumors can be found (Fig. 6 ).
Echography
The clinical appearance of CM and amelanotic tumors (for instance amelanotic melanoma or hemangioma) is sometimes similar. In these cases, US is required to evaluate tumor reflectivity, internal structure, and degree of vascularization. US enables localization of the intraocular mass, estimation of its size, and characterization of its tissue reflectivity. It is a useful exam for measuring tumor dimensions, although the lateral margins of CM are frequently poorly defined (Konstantinidis and Damato, 2017) . Sequential measurement of thickness is also important in the follow-up of patients and to assess treatment response.
The US features of CM are characterized by a flat or a slightly domeshaped mass with a medium-to-high non-homogeneous reflectivity, unlike choroidal melanomas that are more frequently dome-shaped T. Mathis et al. Progress in Retinal and Eye Research 68 (2019) 144-176 with a low-to-medium homogeneous reflectivity (Sobottka et al., 1998; Verbeek et al., 1994) . The typical melanoma A-scan ultrasonography shows high amplitude initial echoes with a low amplitude internal reflection compared to the moderate amplitude of spike in case of CM (Fig. 7) . Moreover, CM are often multilobular with an irregular surface (Sobottka et al., 1998) . Exudative peritumoral or gravitational retinal detachment can be seen (Perri et al., 1992; Verbeek et al., 1994) , with rare choroidal detachment (Sneed et al., 1991) . The differences in US characteristics between CM and choroidal melanoma are explained by the histoarchitecture of the tumor. For example, CM from the breast has solid epithelial nests or glandular structures, which act as echo-producing interfaces, resulting in high reflectivity and an irregular internal structure in US (Perri et al., 1992; Verbeek et al., 1994) . Melanomas, however, are dense cellular masses of low-to-moderate vascularization with only a few necrotic areas, thus containing few echo producing interfaces. As a result, these tumors are of low-to-medium reflectivity with a regular internal structure (Fuller et al., 1979; Goldberg and Hodes, 1977; Sobottka et al., 1998; Verbeek et al., 1994) .
The growth pattern of CM differs to that of melanomas. While metastases appear to infiltrate diffusely the normal choroidal tissue, melanomas are tumors that grow slowly and usually expand through an intact Bruch membrane (Coleman et al., 1974; Ferry and Font, 1974; Sobottka et al., 1998) . They grow in a nodular configuration, thickening the choroid, and progression ultimately leads to the rupture of Bruch's membrane, giving the classical mushroom shape (Coleman et al., 1974; Goldberg and Hodes, 1977; Sobottka et al., 1998) . This difference in growth pattern has been confirmed by US. Furthermore, CM are found as flat tumors with a large infiltration of the choroid resulting in an irregular shape in US (Perri et al., 1992) . Conversely, choroidal melanoma has a higher mean tumor thickness, giving it a higher height to base ratio (HBR: 0.6) than metastases (HBR: 0.18) (Coleman et al., 1974; Sobottka et al., 1998) . HBR determined by US potentially enables the discrimination of choroidal melanoma from CM (Fig. 8) .
Choroidal excavation is created by the difference in reflectivity between the abnormal tissue that replaces the choroid and the underlying normal choroid. About two-thirds of melanoma lesions are associated with choroidal excavation, while it is found in only up to a fifth of CM. (Coleman et al., 1974; Fuller et al., 1979; Sobottka et al., 1998; Verbeek et al., 1994) . Choroidal hemangiomas are also associated with choroidal excavation in about a fifth of cases (Verbeek et al., 1994) .
As the resolution of US is about 50-200 µm (Webb, 1988) , it is more valuable as tumor thickness increases, and is thus mandatory for a precise measurement of large tumors. However, the differentiation between small tumor entities can be challenging, as they could appear similar clinically; in such cases SD-OCT may help as its resolution is about 5 µm (Leung et al., 2008 ) (see section 4.4).
Another application of US associated with Doppler technology is color flow mapping that can display blood flow on the background of the US image (Belden et al., 1995) . Quantitative parameters do not seem useful to determine tumor type and their diagnostic value remains unclear at this time (Neudorfer et al., 2011; Wolff-Korman et al., 1992) . Qualitative parameters seem to be more useful to differentiate choroidal melanomas from CM. Vascular features, such as hypovascularity, with a dominant centrally located vessel with blood flow is typically associated with choroidal melanoma, whereas hypervascularity with lack of dominant vessel is typically associated with CM. Neudorfer et al. have described this 'central pattern' of blood flow in melanoma, contrasting with the 'peripheral pattern' in metastasis (Neudorfer et al., 2011) . Choroidal melanoma. B-scan: dome shaped melanoma with a regular hyporeflective internal structure associated to a choroidal excavation seen as a low reflective step down within the concave highly reflective posterior pole. A scan: the tumor surface-spike is high, followed by quickly decreasing amplitude in the tumor, until the scleral spike; B. Choroidal metastasis. The medium to high reflectivity seen on B-scan is demonstrated on A-scan by moderate variable amplitude of spike following the high amplitude of the tumor surface.
Angiography
Fluorescein angiography (FA) is generally not decisive for the diagnosis of CM (Meyer and Augsburger, 1999) because almost all choroidal tumors have the same angiographic features: usually hypofluorescent in the early phase and heterogeneously hyperfluorescent in the late phase. In some cases, pinpoints and leakage areas are seen on the mass (Konstantinidis and Damato, 2017) (Fig. 9) .
Conversely to FA, ICGA helps in the differential diagnosis of choroidal tumors. CM are usually defined as hypofluorescent at all phases on an underlying isofluorescent background (C. L. Shields et al., 1995a) , and the "double circulation" pattern, first described in choroidal melanoma by Augsburger, is generally not found in CM (Augsburger et al., 1984; Konstantinidis and Damato, 2017) . Furthermore, due to better visualization of the choroid, ICGA generally shows a larger area of choroidal involvement of the metastases than does clinical examination or FA (Fig. 10) .
Blue light fundus autofluorescence shows a heterogeneous pattern with areas of hypo and hyper-autofluorescence (Ishida et al., 2009; Natesh et al., 2010) . This exam detects lipofuscin in the RPE, which is disturbed in cases of RPE alterations. This pattern is also found in hemangioma or choroidal melanoma.
Optical coherence tomography
The small size and posterior location of most CM ) make these tumors ideal candidates for investigation using OCT. Anatomical features on SD-OCT, enhanced depth imaging (EDI)-OCT, and OCT-angiography (OCTA) can help identify the type of choroidal tumor, and are most useful for the follow-up of the tumor aspect, size, and retinal consequences.
Choroidal thickness estimated by optical coherence tomography
Time domain OCT was limited for the exploration of choroidal T. Mathis et al. Progress in Retinal and Eye Research 68 (2019) 144-176 structures, including CM (Arevalo et al., 2005) . SD-OCT with EDI, and more recently swept-source OCT, have improved our understanding of the choroid and provided detailed information about the morphological features of choroidal tumors (Demirci et al., 2014; Ferrara et al., 2016; Ishida et al., 2017) . In EDI-OCT, CM has a low internal optical reflectivity, with an enlarged suprachoroidal space (Cennamo et al., 2017) . The internal reflectivity can increase after treatment. EDI-OCT is also more sensitive for the detection of very small CM before they are clinically visible (Al-Dahmash et al., 2014; Torres et al., 2011; Witkin et al., 2012) and it is estimated that 20% of CM are visible only on EDI-OCT (Demirci et al., 2014) . For instance, in a series of 31 eyes with CM, tumors as small as 550 μm were imaged using EDI-OCT but were not readily identified by US or ophthalmoscopy; they were located in the outer choroid, with a loss of large choroidal vessels (AlDahmash et al., 2014) .
Although some lesions are visible both in US and EDI-OCT, US overestimates thickness by 55-133% according to tumor size (AlDahmash et al., 2014; Demirci et al., 2014; Shields et al., 2012 ) and the mean difference in tumor thickness between the two modalities was found to be 536 μm (Demirci et al., 2014) . This difference is explained by the greater axial resolution of EDI-OCT (Webb, 1988) compared to US (Leung et al., 2008) that allows a more precise placement of calipers with respect to surrounding ocular structures, and which is most useful for very small choroidal lesions (Fig. 11) .
Specific signs in optical coherence tomography
In addition to tumor thickness, OCT allows to visualize specific patterns associated with CM. The most noticeable feature is the irregular or "lumpy bumpy" anterior surface of the lesion, despite an apparently smooth surface on US (Al-Dahmash et al., 2014) . This aspect is different from the smooth "mound" of nevus or the smooth "dome" of melanoma, and can help identify the type of choroidal tumor (Table 3 and Fig. 12 ).
Another sign frequently associated with CM is SRF. This is found in 67-95% of cases, mostly with hyper-reflective dots within the SRF that are known as speckles (Al-Dahmash et al., 2014; Demirci et al., 2014; Vishnevskia-Dai et al., 2016) . These dots may be shed photoreceptor outer segments in longstanding SRF overlying CM (Demirci et al., 2014) . The optical density or substance reflectivity of the SRF can also be measured by OCT, and can be indicative of the cause of SRF (Baek and Park, 2015; Neudorfer et al., 2012) as the optical density ratio of SRF was found to be significantly lower in CM than in melanoma (Leshno et al., 2017) . This suggests that the composition of the SRF, mainly its protein content, is different between tumor types. As the composition may change over time, one can assume that fluid detected earlier would have a lower protein concentration and a lower optical density than fluid that is detected later during disease progression. Because CM are usually in the posterior pole, they become symptomatic and are evaluated by OCT earlier than choroidal melanoma. This may explain why the SRF has a low optical density at time of evaluation. Conversely, choroidal melanoma can be peripheral and asymptomatic Retinophotography using ultra-wide field scanning laser ophthalmoscopy. Note the green hue of melanotic lesions due to red-green laser imaging; E. Intermediate phase FA showing patchy hyperfluorescence with typical hyperfluorescent pinpoints; F. ICGA showing less well defined boundaries, a size matching that of the fundus, and no intratumoral vessels in this case. 
Table 3
Optical coherence tomography features of the anterior surface of various choroidal tumors (according to Al-Dahmash et al. (2014) Abrupt smooth dome-shape T. Mathis et al. Progress in Retinal and Eye Research 68 (2019) 144-176 for a long time, and therefore imaging may occur after a longer duration of SRF secretion, when it has a higher optical density. Another explanation could be the difference in the vascular properties of the tumors. For instance, CM have been shown to be more hypervascularized than choroidal melanoma (Neudorfer et al., 2011) and a higher vascular permeability may affect the composition of the SRF and cause the lower optical density observed in metastasis. Other OCT features of metastatic tumors include shaggy photoreceptors, alteration of the ellipsoid zone, RPE changes (atrophy or hyperplasia), and choriocapillaris compression (Demirci et al., 2014) (Table 4 and Fig. 13 ). Despite the variety of described OCT features in CM, we did not identify any difference in features according to the type of primary cancer.
OCT is also useful in the follow-up of choroidal lesions after therapy, especially to monitor changes in thickness, quantity of SRF, shaggy photoreceptor appearance and reflectivity, which can confirm the anatomical effectiveness of therapy. As mentioned earlier, the internal optical reflectivity of the tumor increases as the metastatic tumor becomes inactive, consistent with an increase in fibrotic tissue content (Demirci et al., 2014) .
Optical coherence tomography-angiography
OCT angiography (OCTA) is a non-invasive, high speed based imaging technique enabling visualization of blood flow in the retina and choroid through comparison of successive A-scans (Borrelli et al., 2018; Spaide et al., 2018) . OCTA may help differentiate tumors as in CM there is a lack of flow at the level of the lesion and absence of pathological blood flow in the outer retinal layer, whereas in choroidal melanoma, hemangioma, and osteoma there may be a dense, irregular vascular network inside the tumor and even increased flow in the outer nuclear layer (Cennamo et al., 2017) . This seems contradictory to US Osteoma: lamellar-shape, associated to SRF; C. Hemangioma: abrupt smooth dome-shaped, no retinal pigment epithelium (RPE) changes; D. Nevus: smooth mound-shaped, can be associated with RPE changes; E. Melanoma: dome-shaped, RPE changes, outer retina alterations.
Table 4
Optical coherence tomography features of choroidal metastasis (according to Al-Dahmash et al. (2014) findings of hypervascularity in CM (Neudorfer et al., 2011) , but the lack of flow detection may be explained by the masking effect of the RPE on the underlying tumor neovascularization, or by a fringe washout due to higher flow speed inside the tumor (Chen et al., 2016; Spaide et al., 2015) (Fig. 14) .
Neuro-imaging: CT-scan and MRI
Computed tomography (CT) of the eye is rarely useful in cases of ocular tumors. Magnetic resonance imaging (MRI) shows a well-defined choroidal mass that appears isointense on T1-weighted images and hypointense on T2-weighted images (Peyster et al., 1988) . The resolution of conventional MRI is limited when it comes to the eye, primarily because of motion artefacts due to blinking and gaze changes, but also because of field inhomogeneity at the air-cornea interface. Additionally, the use of head coils for imaging the eye produces a low signal-to-noise ratio (Atlas et al., 1987; Bilaniuk et al., 1985) . High resolution MRI (HRMRI) limits motion artefacts by using conjugate gaze and cued blinking. Interface artefacts are limited by applying a wetted gauze on the eyelids (Bert et al., 2006) . Surface coils and high magnetic fields (3 and 7 Tesla) also result in a better signal-to-noise ratio (Beenakker et al., 2013) . Several HRMRI studies have been conducted on choroidal melanoma and retinoblastoma. In melanoma, both 1.5 Tesla and 7 Tesla HRMRI better reveal internal structure and scleral invasion than conventional MRI (Beenakker et al., 2013; Lemke et al., 1998; Lindner et al., 2015) . In retinoblastoma, both 1.5 and 3 Tesla HRMRI are established as predictors of metastatic risk, based on scleral, choroidal, and optic nerve invasion (de Jong et al., 2015; Sirin et al., 2015) . To date there are no published in vivo HRMRI patient studies on CM, but it is reasonable to believe that it would be useful when the tumor is not visible because of intravitreal or subretinal hemorrhage, or complete retinal detachment. As resolution increases, HRMRI may give insight on the histological type of the metastasis and help differentiate CM from a primary ocular tumor. Recently, a novel MRI modality, MR microscopy (MRM), was assessed ex vivo for the diagnosis of intraocular lesions. MRM provides resolution in the sub-millimeter range with an excellent signal-to-noise ratio, and has allowed the visualization of tumor ultrastructure with good correlation to histology. This could help differentiate CM from other tumors, but also identify the type of primary cancer (Falke et al., 2013) .
Diagnosis work-up
Up to a third of patients presenting with intraocular metastases have no known history of cancer Shields et al., 1997b) . It is therefore important to manage systemic work-up to identify the primary site of neoplasia. If no primary tumor has been found, biopsy for cytological or histopathological analysis should be considered. Unlike most organs where a biopsy is readily accessible, retrieving a biopsy from a small choroidal lesion requires a skilled and experienced surgeon and carries a risk of intraocular injury. Biopsy is further limited by the necessity of a qualified pathologist and often insufficient or inadequate retrieved material (Cohen et al., 2001) . These limitations highlight the need for a non-invasive ancillary diagnostic test that will help characterize intraocular lesions.
General work-up
The diagnostic work-up depends on whether there is a history of cancer and whether it is already generalized when CM is diagnosed. If the CM is very large (and enucleation is performed), the work-up is usually guided by the histological findings. If there is no history of primary tumor, a thorough medical history (including gender, smoking habit, previous breast cancer screening) and physical examination is required and will guide the ophthalmologist in the search for primary tumor. In cases with known metastatic dissemination, past medical history is usually sufficient to guide ocular and general treatment. In cases where there is a history of cancer but no history of metastases, diagnostic work-up should be specific to the suspected cancer type; it may include mammograms, positron emission tomography (PET)-CT, etc.
Tumor biopsy
Rationale
Histological proof of cancer is generally required by oncologists to guide treatment (Chin et al., 2007; Overgaard, 1996) . The eye is, however, an exception to this rule, as intraocular tissues are not readily T. Mathis et al. Progress in Retinal and Eye Research 68 (2019) 144-176 accessible for biopsy, and it is accepted to start treatment without cytological or histological confirmation in case of uveal melanoma (Foulds, 1992; Harbour, 2007) . Tumor biopsy is nowadays widely used for the prognostication in choroidal melanoma and can help the oncologist determine the risk of metastasis (Damato, 2018; Damato et al., 2011) . However, in CM, the aim is quite different because biopsy is mostly indicated to determine the type of primary tumor when it is still unknown after a thorough systemic work-up . Although a tissue sample will support the diagnosis, obtaining it is not without risk for the vision or life of the patient, and the risk-benefit ratio must be considered. It is thought that intraocular biopsy may increase the risk of dissemination of malignant cells, and presents a risk of severe ocular complications, which may explain its limited use (Eide and Walaas, 2009 ). However, intraocular tumors are generally accessible to sampling using fine needle aspiration biopsy (FNAB) transsclerally or transvitreally (Augsburger et al., 2015; McCannel et al., 2012; Sellam et al., 2016; Singh et al., 2016) . This technique does not consist of an actual biopsy, but rather cytological tissue sampling. The aim is to confirm the metastatic nature of the tumor, and to help determine the likely site of primary malignancy in order to plan imaging and complete workup accordingly (Eide and Walaas, 2009; Shields et al., 1993) .
One of the limitations of FNAB is the risk of inadequate sampling, resulting in false negatives, which must be considered when dealing with small tumors. The experience of the cytopathologist is important to reduce this risk, as decisions need to be made on a small number of cells. Optimally, the cytologist should be present in the operating room to ensure that an adequate amount of biopsy material is obtained .
Another technique, more recently described, consists of an intraocular biopsy using the vitreous cutter or special forceps penetrating directly into the tumor and is highly effective in obtaining a tissue sample (Akgul et al., 2011; Bagger et al., 2013; Konstantinidis et al., 2014; Sen et al., 2006; Seregard et al., 2013) . A transscleral incisional biopsy with forceps, recently described by Angi et al. in cases of choroidal melanomas, could yield more successful histological analysis (Angi et al., 2017) .
Ocular tumor biopsy is most useful in patients with atypical clinical findings, when it is challenging to differentiate between CM and primary choroidal melanoma, or when systemic investigation has failed to identify primary malignancy. In our opinion, any discordance between non-invasive tests should warrant ocular tumor biopsy to confirm the histological nature of the tumor. For instance, in a group of patients with intraocular masses, major diagnostic uncertainty was reported in 2.4% of cases (159 of 6500 patients evaluated) . In these patients, a biopsy was required in order to establish the diagnosis and to initiate the appropriate treatment. FNAB yielded adequate cytological material in 88% of cases. Furthermore, when no primary tumor is identified by systemic workup, tissue sampling has been shown to successfully confirm the metastatic nature of the lesion and identify its origin in most cases (Akgul et al., 2011; Konstantinidis et al., 2014; Sen et al., 2006) .
In addition to histological confirmation, tumor biopsy can also help to identify specific molecular alterations, some of which may be targeted by so-called targeted therapies. For example, in breast cancer, immunohistochemical evaluation can identify patients with HER2/neupositive disease, which is associated with a higher risk of recurrence, and may benefit from adjuvant anti-HER2/neu-directed therapy (Wolff et al., 2007) . Furthermore, histopathological evaluation can identify estrogen and/or progesterone receptor-positive tumor cells, predicting benefit from endocrine therapy (Hammond et al., 2010) . In non-small cell lung cancer, deoxyribose nucleic acid (DNA) can be extracted from the residual biopsy material and assessed for the presence of epidermal growth factor receptor (EGFR) mutations. When these are present, targeted therapy with EGFR-tyrosine kinase inhibitors, such as gefitinib and erlotinib, has been shown to increase survival in lung carcinoma patients. In the same manner, a rearrangement of the Anaplastic Lymphoma Kinase (ALK) gene in a subset of lung adenocarcinomas, leading to an activation of the ALK kinase, can be specifically treated by molecules targeting ALK, such as crizotinib (see section 6.2) (Lin and Yang, 2011; Rosell et al., 2012) . KRAS mutation can also be tested, especially in cases where colorectal cancer is suspected (KRAS oncogene is mutated in 35-45% of colorectal cancer and is a biomarker of poor response to anti-EGFR therapy (Karapetis et al., 2008; Van Cutsem et al., 2009) ).
Technique
FNAB of choroidal tumors takes practice, and sometimes several attempts before yielding useful material (McCannel, 2013) . Depending on the tumor site, it may be performed by transscleral or transvitreal approach. The transscleral approach, which is easier and more widespread, is indicated for pre-equatorial lesions, and for large lesions away from the posterior pole (lesions > 10 mm at the base, > 3 mm in height, and with the anterior border halfway between the equator and the optic disc) (Eide and Walaas, 2009) . It involves placing the needle through the sclera and into the tumor after precise localization by transillumination and indirect ophthalmoscopy if necessary. This procedure can be performed at the same time as the placement of brachytherapy plaques or tantalum fiducials (for proton therapy). Small lesions with a posterior location, especially if they are thin, are more safely biopsied with a transvitreal approach (Shields et al., 2007a (Shields et al., , 2007b . The transvitreal FNAB is performed by inserting a needle through a sclerotomy at the opposite of the tumor, which is visualized directly with a wide-field lens. The needle is then inserted transretinally into the tumor and material aspirated (Augsburger et al., 2015; McCannel et al., 2012; Sellam et al., 2016; Singh et al., 2016) .
The biggest challenge with FNAB is to obtain sufficient material for analysis. In general, the yield is greater for large tumors, but they may contain areas of necrotic material which is not useful for the pathologist. Several passes may be necessary in order to obtain sufficient material (McCannel, 2013) .
A variation of transvitreal needle biopsy consists of aspirating inside the tumor using a 25 gauge vitrector, with (Bechrakis et al., 2002) or without prior vitrectomy (Bagger et al., 2013; Konstantinidis et al., 2014; Sen et al., 2006) . This method was shown to yield larger tissue samples with a 92% chance of successful diagnosis (Sen et al., 2006) . Another variation of this technique is to use biopsy forceps after small incision at the chosen biopsy site (Akgul et al., 2011; Seregard et al., 2013) .
Transvitreal choroidal biopsies for tissue sampling have become more common over recent years due to the improvement of surgical techniques such as sutureless 25-gauge vitrectomy that reduces surgical trauma.
Complications
It is accepted in oncology that a tumor biopsy carries a risk of tumor cell dissemination, increased rate of local recurrence, and increased risk of metastatic development. However, this has not been reported for biopsy of CM or choroidal melanoma. To the best of our knowledge there is no report of secondary tumor implantation at an eye wall entry site used for biopsy, nor any report of enucleation secondary to biopsy complication. Other local complications may include intravitreal hemorrhage or retinal detachment. For instance, in a series of FNAB reported by Augsburger et al., about 60% of patients undergoing FNAB had any-grade vitreous hemorrhage (Augsburger et al., 2015) . However, in a recent series reported by Grixti et al., only 20/739 eyes (2.7%) that underwent choroidal tumor biopsy required vitreoretinal surgery for biopsy-related complications including persistent vitreous hemorrhage in 14 eyes, rhegmatogenous retinal detachment in 5 eyes, and endophthalmitis in 1 eye (Grixti et al., 2014) .
Guidelines
Tumor biopsy should only be performed when it is likely to provide a diagnosis and this is largely determined by tumor thickness, especially for FNAB. There is a strong correlation between the rate of successful diagnosis from a FNAB and the thickness of the lesions on US (< 1.9 mm: 40%; 1.9-4 mm: 90%; > 4 mm: 98%) (Cohen et al., 2001) , and it is also of note that sufficient aspirate was obtained in almost twothirds of tumors that had a thickness of 1.5-3 mm (Augsburger et al., 2002) . Overall, FNAB can be expected to give useful information in lesions > 3 mm in thickness, but is unreliable in lesions thinner than 2 mm (Eide and Walaas, 2009) . No thickness cut-off has been described for transvitreal biopsy using the vitreous cutter or forceps (Damato, 2018) .
As a rule of thumb, it is unnecessary to perform an eye biopsy in a patient with multi-organ metastases if the primary tumor is known. If it is not known but other systemic metastases are present, the more readily accessible metastasis should be favored for biopsy. Nevertheless, the risk of ocular complications associated with biopsy should always be taken into consideration in the decision and discussed with the patient prior to the procedure.
Liquid biopsies
When cytology of the CM cannot be obtained, liquid biopsy could provide additional diagnostic clues. This emerging non-invasive diagnostic method usually consists of blood samples (saliva and urine are also possible) that are used to identify biomarkers of microscopic tumor dissemination, such as circulating cancer cells or circulating tumor DNA, and are mostly used to guide treatment and to monitor response during follow-up (Heitzer et al., 2015) . For example, a liquid biopsy was used in a patient with bilateral CM to detect both circulating thyroid transcription factor 1 (TTF1) positive cells and EGFR mutation that allowed the diagnosis of lung cancer and the treatment by anti-EGFR therapy (Bouhlel et al., 2017) . Moreover, circulating tumor DNA and its mutational load has been identified as a marker of effectiveness of systemic treatments in breast cancer and may be used to switch treatment line before clinically evident disease progression (Hench et al., 2018) .
Multimodal treatment: the strategy
Clinical context
Complex treatments are generally controversial for CM because metastatic patients are believed to have limited life expectancy and thus derive minimal benefit from the treatment of CM. One should, however, consider the broad spectrum of metastatic disease. As emphasized by Hellman and Weichselbaum, survival can vary from weeks to years according to whether patients have widely diffuse metastases or oligometastatic disease (Hellman and Weichselbaum, 1995) .
One of the aims of the treatment of metastatic disease is to improve progression-free survival. This palliative approach implies a short delay of care, short and minimally invasive procedures, rapid functional results, and a low rate of treatment-induced complications. Depending on the performance status of the patient and the type of primary cancer, the progression-free survival could, however, be drastically different. Multimodal treatment of metastatic disease is also increasingly being used to cure patients. Zacharakis et al. have recently reported a complete and durable (more than 22 months) regression of a chemoresistant metastatic breast cancer treated by specific tumor-infiltrating lymphocytes (Zacharakis et al., 2018) , and overall survival in cases of breast or renal cancer after more than ten years of metastatic disease is not unusual.
Mortality in patients with CM is correlated with the presence of synchronous metastasis in the liver or lungs (d 'Abbadie et al., 2003) . For instance, patients with breast cancer had survival rates of 65% at 1 year, and 24% at 5 years after diagnosis of CM (Demirci et al., 2003) . In another series reported by Shah et al., 1-year survival was 46% in CM patients with lung cancer (Shah et al., 2014) . In light of these data, the term "metastatic patient" needs to be cautiously interpreted. Taking into account personalized prognosis allows the most appropriate treatment strategy to be chosen, which is especially true in end-stage disease as the primary goal of the physician must remain to do no harm; it implies weighing the potential benefits of a medical intervention against the annoyance it may cause, allowing the patient to retain the highest possible quality of life.
Although it is often overlooked in oncology, loss of visual function is a major issue in patients with ocular metastases as they may quickly loose autonomy. The treatment aims to prevent or reverse visual function loss in order to improve the patient's quality of life. It can also help prevent serious psychological consequences, by avoiding enucleation for example (Demirci et al., 2003; Shah et al., 2014) . While it may be challenging for ophthalmologists to make a therapeutic decision in the context of metastases, one should not wait too long as the risk of irreversible blindness is probably related to the duration and severity of tissue injuries before treatment.
The decision to pursue local therapy for CM is multidisciplinary, involving the patient, oncologist, ophthalmologist, and radiation oncologist. Important considerations include overall health, life expectancy, location and extent of intraocular lesions, visual symptoms, and patient preferences. A detailed office evaluation is performed before treatment (indirect ophthalmoscopy, fundus drawing, photography, FA, ICGA, OCT, and US) to measure tumor size and evaluate whether it threatens the optic disk or fovea.
In case of isolated CM or oligometastatic disease: a local treatment is considered upfront. If general prognosis and performance status are relatively good, and the available therapeutic resources are not too invasive, local treatment is proposed with a good chance to retain or restore visual function. In such cases, depending on histology and ocular extent, focalized radiation techniques may be proposed, such as brachytherapy or proton therapy, or stereotactic body radiation therapy with appropriate eye tracking.
In case of multimetastatic disease threatening survival: life threatening metastases are treated with a combination of systemic and sometimes local treatments. The local treatment of CM is usually postponed, definitively or until overall metastatic disease is properly controlled. There are exceptions if the ocular symptoms are very intense and there is a long delay before chemotherapy (due to organizational reasons); in such cases, short palliative radiotherapy can be done in the first place.
Systemic therapies
Do systemic therapies effectively reach the choroid?
There are three ways to deliver drugs to the eye: topical, intraocular, and systemic. Topical drugs are quickly drained away and the intravitreal bioavailability is estimated to be 0.0001-0.0004% (Maurice, 2002) , and in practice this route is not used for the delivery of oncological treatments for intraocular tumors. The intraocular administration allows the highest intravitreal or intraretinal drug concentration, as it bypasses the blood-ocular barrier (Jordán and Ruíz-Moreno, 2013 ) that works as a filter between the general circulation and the retina to maintain a protected micro-environment around the neuroretina. It is composed of the blood-aqueous barrier (anterior) and the blood-retinal barrier (posterior). The latter is divided into the inner blood-retinal barrier, formed by tight junctions between the retinal capillary endothelial cells, and the outer-blood retinal barrier, formed by tight junctions between the RPE cells (Hosoya and Tomi, 2005) . The retina is therefore described as a "sanctuary" protected by barriers on both sides. Similarly to the blood-brain barrier, it makes it difficult for systemic drugs to reach the retina (Del Amo et al., 2017) . As for the choroid itself, the notion of sanctuary is challenged by the presence of fenestrated endothelium in the highly vascularized choriocapillaris.
This high permeability may allow rapid entry of drugs from the blood to the extravascular choroid (Bill et al., 1980 (Table 5 ). In non-small cell lung cancer for example, specific EGFR mutations make it sensitive to tyrosine kinase inhibitors such as gefitinib or erlotinib. Anaplastic lymphoma kinase (ALK) gene rearrangement can also be targeted with specific drugs such as crizotinib. As discussed above, liquid biopsies could become sufficient to detect activated oncogenes and drug susceptibility in the near future, allowing a precise diagnosis and targeted therapy without the need for an invasive biopsy (Bouhlel et al., 2017) .
Yang et al. reviewed the literature and found only 12 cases (between 1995 and 2014) treated with systemic chemotherapy alone (several chemotherapy regimens) instead of local therapy. At least two cases had only CM and no other distant metastasis. Eight (66.7%) of them demonstrated CM regression after treatment with survival ranging from 3 to more than 18 months after CM diagnosis. They did not report the delay nor the duration of the response (Yang et al., 2014) . Shah et al. described 22 patients with lung cancer treated by chemotherapy alone with regression of CM in 68% of cases, whereas 15 eyes managed by observation showed regression in only 20% of cases (Shah et al., 2014) .
In breast cancer.
There are fewer reported cases of breast cancer CM responding to systemic treatment, and most of these concern patients with high tumor expression of estrogen and progesterone receptors. This represents about 80% of breast cancer cases, and is associated with better systemic prognosis, but also with a higher rate of choroidal involvement (Parrozzani et al., 2016) . Interestingly, the majority of such cases had a good ocular response to hormonal monotherapy (Table 6 and Fig. 15 ). Human epidermal growth factor receptor 2 (HER2) -positive breast cancer is prone to brain metastases; whether it is also prone to CM is less well understood. HER2 inhibitors such as trastuzumab have been a major advance in oncology, allowing to reverse the poor prognosis associated with HER2 overexpression. HER2 mutation can be associated with high hormonal receptor (HR) expression, and in such cases a combination of targeted drugs is used. In about 17% of cases, patients have triple negative breast cancer (i.e. HER2, estrogenic, and progesterone receptors are not expressed) (Dent et al., 2007; Haffty et al., 2006) . These are more likely to develop metastases within 5 years of diagnosis and there are fewer effective systemic drugs. Current evidence shows that triple negative and HER2-positive breast cancers have a higher rate of brain metastases, but the hormonal receptor positive cases (especially the luminal B subtype) are more likely to develop CM (Parrozzani et al., 2016) .
As a decision support tool, the overall survival rates of stage IV breast cancer according to the different subtypes are as follows (data from the USA) Howlader et al., 2018) . All types: 26.5% at 5 years; HR-positive and HER2-negative (mostly luminal A subtype): 35.9% at 4 years; HR-positive and HER2-positive (luminal B subtype): 45.5% at 4 years (the difference between this subtype and the HR-positive/HER2-negative is likely due to the effectiveness of HER2-targeted therapies); HR-negative and HER2-positive (subtype HER2-enriched): approximately 34% at 4 years; HR-negative and HER2-negative (triple negative): 11.2% at 4 years.
In other primary cancers.
There are very few reports of CM from malignancies other than breast or lung cancer, and most of these were managed by external beam radiation therapy (EBRT), with or without systemic therapy. Essadi et al. reported a case of a CM from clear-cell renal carcinoma successfully treated by everolimus alone (an inhibitor of mammalian target of rapamycin, mTOR) as second-line systemic treatment (the patient also had lung metastases). The patient had complete recovery of vision at 4 months and partial response as assessed by tumor size (Essadi et al., 2017) . In CM from prostate cancer, some case reports have shown the effectiveness of hormonal blockade monotherapy (Primavera et al., 2008) .
It should be kept in mind that the prognosis of stage IV disease status varies greatly among the types of cancer. For instance, in a study of 1028 patients with metastatic renal cell carcinoma, those who had no identified risk factor survived several years (mean: 43.2 months) with a good quality of life (Heng et al., 2013) , whereas in metastatic prostate cancer, one in four men survived more than five years (Wu et al., 2014) . This illustrates the necessity of close cooperation between the ophthalmologist and the oncologist in order to properly consider the risks and benefits of CM treatment.
Targeted therapies: can they replace local treatment?
The multiple reports of improvement or stabilization of vision under targeted therapy are encouraging, both for the patient and the ophthalmologist (Tables 5 and 6 ). In such cases, one may argue that local treatment, together with the risk of serious side effects it carries, is unnecessary. However, some limitations must be considered. For instance, evidence is only provided by case reports with limited follow-up (usually less than one year) and therefore the level of proof is not sufficient to assert the superiority of targeted treatments on CM. There may even be a reporting bias, as cases where systemic treatment was not effective on CM are probably under-reported. In the absence of randomized studies, and given the scarcity of oncological studies with a specific focus on CM, no definite conclusion can be drawn. Furthermore, it appears that systemic treatment may have a lower rate of initial response and a higher rate of ocular relapse compared to local treatment (and results presented as positive after systemic treatment may not make the distinction between complete and partial clinical response). However, consolidative local treatment is helpful in achieving a higher response rate, and preventing ocular relapses. For instance, in a series of 194 patients with uveal metastases of lung cancer, partial response was reported in 68% of patients receiving systemic treatment alone, versus 82-86% of patients receiving additional local treatment by photon-based-EBRT or brachytherapy; regrowth at one year occurred in 32% of patients receiving systemic therapy, versus 14-18% of patients who had local treatment (Shah et al., 2014) .
Systemic molecular treatments are also subject to secondary resistance due to clonal selection, which is less the case for local physical treatments. Because of this, response to targeted therapies may not be durable, preventing the use of the same molecule in retreatment. Illustrating this point is a case report of a patient with lung cancer who developed CM while receiving crizotinib, prompting the switch to another ALK inhibitor achieving only partial ocular response (Okuma et al., 2015) . Similarly, Cui et al. reported the case of a single CM, also from ALK-mutated lung cancer, which was treated successfully with crizotinib but later became resistant and developed a second CM in the same eye. A switch to another ALK inhibitor led only to a partial response. Visual acuity improved from 20/200 to 20/50 after treatment of the first CM, and from 20/200 to 20/60 after the treatment of the second CM (Cui et al., 2017) . These examples suggest that regression of CM is a good reflection of tumor sensitivity to the systemic therapy. However, this regression can be falsely reassuring, and postponing local treatment may have consequences on visual function. Thus, initial CM response may not be clinically relevant when deciding to treat locally or not. Finally, the possibility of adverse ophthalmological events with systemic treatments should not be forgotten (Liu et al., 2014) . For instance, mitogen-activated protein kinase kinase (MEK) inhibitors have been widely reported to be associated with uni-or pluri-focal serous detachments of the neurosensory retina, with spontaneous regression (Francis et al., 2017; Weber et al., 2016) . EGFR inhibitors are also associated with ocular toxicities, most commonly dysfunctional tear syndrome, blepharitis, and eyelash changes (Borkar et al., 2013 ).
Table 5
Cases of patients with CM and lung cancer treated by systemic therapy only published in the last 10 years (English language). Crizotinib and alectinib are tyrosine kinase inhibitors indicated in lung cancer with rearrangement of Echinoderm Microtubule Associated Protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) genes; erlotinib and gefitinib are anti-epidermal growth factor receptor (EGFR) drugs. Gene mutations were identified in lung tumor before administration of the specific anti-tyrosine kinases; PD-L1: programmed death ligand 1; CM: choroidal metastases; NR: not reported. Regression of tumor size after 1-2 months
Two patients died at 3 and 6 months after the diagnosis of CM, one survived more than 16 months with no recurrence of his unique CM at 6 months.
Gefitinib (1 patient)
General and CM progression Died 3 months after the diagnosis of CM 
Then crizotinib
Partial systemic response but no improvement of vision with chemotherapy.
General and ocular response at 12 months with crizotinib.
At 3 months, tumor size decreased by 39%. Improvement of vision 3 weeks after beginning crizotinib.
Okuma et al. (2015) 1 Non-small cell lung cancer, EML4/ALK rearrangement, PD-L1 expressed
Third-line anti PD-L1
General and ocular disease progression.
Fourth-line alectinib
General and ocular improvement in 1 week. Vision completely recovered within 2 weeks. Partial response for more than 5 months. General disease regression, improvement of vision after 5 months. Survived more than 15 months after the diagnosis of CM.
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Radiotherapy for choroidal metastases
Radiotherapy techniques
There are various forms of radiotherapy and various fractionation schemes depending on the local extent of the disease, its proximity to the macula, the number of lesions, the general prognosis, and the treatment goals. Another major factor is tumor radioresistance, in which case a higher total dose is required. There are also technical constraints governing the choice of the technique. They include dose conformality, dose spillage, treatment duration (beam delivery), the possibility to use numerous small doses or a single large dose, and of course access to the technique. All these integrate a patient-specific risk-benefit ratio, bearing in mind that healthy tissues are better spared with smaller doses per fraction while there is a spectrum of dose-response patterns for primary cancer. Radiotherapy techniques used to treat CM are presented below and include brachytherapy (contact brachytherapy with plaques) and external beam radiotherapy (EBRT) that itself includes tridimensional (conventional) EBRT, intensity modulated EBRT (IMRT), fractionated stereotactic EBRT (SBRT), stereotactic radiosurgery (single fraction SBRT), and proton beam therapy (PBT). Dose distribution, treatment planning and cost vary widely between these techniques. Conventional EBRT with photons is the most common treatment for CM as it is cost effective and readily accessible worldwide (it is commonly called EBRT).
Complications of radiotherapy may occur months or years after irradiation, which is relevant to long-term survivors. Depending on prognosis, the aims of radiotherapy are not only to control tumor growth, but also to preserve vision in the long term by sparing the macula and the optic disc. When possible, the anterior chamber is excluded from the irradiation field. CM that occur secondary to radioresistant tumors (for instance melanoma, renal cancer, or sarcoma) are more likely to respond to high-dose radiotherapy. On the other hand, the macula is also sensitive to radiation. Thus, the radiotherapy technique and treatment scheme should be adapted carefully after evaluation of the risk-benefit ratio (Fig. 16) .
Basic radiophysics and radiobiology.
The cellular response to radiation is caused by interaction of ionizing radiation with DNA. Its clinical effect relies on differences in damage response pathways between tumor and normal tissues. At the molecular level, ionization of molecules through water radiolysis produces reactive free radicals which secondarily react with neighbouring materials, including DNA. DNA damage schematically includes single or double strand breaks and base/sugar damages. Higher linear energy transfer radiation, using charged particles (protons, carbon ions, etc.), also induces direct effects on molecules and higher concentration of ionizing events. It is more likely to produce complex DNA damage than low linear energy transfer radiation as achieved with EBRT, IMRT, SBRT, and brachytherapy. Regression of tumor thickness from 1.5 mm to 0.4 mm at 2 months; complete regression at 6 months and after 18 months. Preservation of visual acuity.
Expression of human epidermal growth factor receptor 2 (HER2) or hormonal receptors was identified in the tumor before administration of trastuzumab or hormone therapy (tamoxifen and aromatase inhibitors, including letrozole) respectively. CM: choroidal metastases. More complex DNA damage is associated with less efficient DNA repair and higher anti-tumor activity (Lomax et al., 2013) . The radiobiology of stereotactic radiosurgery is not fully understood but it is thought that it delivers a greater biologically equivalent dose, and that different molecular mechanisms are involved. This would account for a better local control rate than with conventional EBRT, even in radioresistant tumors (Shibamoto et al., 2016) . Intriguingly, the dose necessary to achieve CM control seems to be lower than that used for primary tumors. It may be that choroidal tumor burden is limited but the precise mechanisms for such observations are unclear.
Organs at risk in ocular radiation oncology.
There is a doseresponse relationship for the tissue effects of radiation therapy (Table 7) and therefore treatment decision is based on the tolerance of a given organ or tissue to a given dose based on previous knowledge. The dose threshold is either given as maximal or mean dose (and associated dose volume relationships) depending on whether the organ is considered to have "serial" or "parallel" architecture (by analogy with electricity). Serial organs are sensitive to hot spots while parallel organs are sensitive to relatively lower doses in larger portions of their volume. Fractionation plays a major role in the tolerance of healthy organs and tissues. Normofractionation of 2 Gray (Gy) per fraction is the standard curative radiotherapy scheme. Alternative fractionation may be used in different situations, including metastases. Equieffective dose is then calculated from the dose per fraction and the duration of the treatment to estimate tumor response and normal tissue tolerance. For CM, the most common regimen of 30 Gy in 10 fractions is estimated to be equivalent to around 38-40 Gy in normofractionation (Kuperman, 2018) . A total dose of 40 Gy is under the critical "toxic" threshold for maculopathy. This may explain the good visual preservation rate obtained with conventional EBRT using this common radiotherapy scheme for CM. However, pathological changes to the eye due to the CM or other health conditions may also influence the organ's tolerance and visual preservation after radiotherapy.
Hypofractionation (i.e. fraction dose greater than 2.5 Gy and shorter
Fig. 16. Techniques of radiation therapy and corresponding radar charts. Brachytherapy (A) External beam radiotherapy techniques (B, C and D). A.
Brachytherapy is a conformal technique that does not deliver dose outside the eye. The principle is to apply radioactive isotope to the sclera that will deliver radiation over a short distance to the tissue. The plaque delivers a heterogeneous dose from the sclera to the apex of the tumor; B. Conventional 3D radiotherapy delivers a uniform dose to the eye using 1 to 3 fields. Intensity modulated radiotherapy (IMRT) uses instead 5 to 9 fields and a multileaf collimator, allowing complex concave dose distribution; C. Stereotactic beam radiotherapy (SBRT) delivers radiotherapy from many different positions around the organ so that the beams meet at the tumor. The tumor receives a high dose of radiation and the healthy tissues around it only receive a low dose; D. Proton beam therapy (PBT) allows a very focused and high-dose volume due to the physical properties of protons. The energy is delivered with a sharp final peak allowing preservation of surrounding tissues. treatment course) is associated with an increased risk of cataract (Belkacémi et al., 2001; Thariat et al., 2017) . It can be reduced by lens shielding and lens-sparing techniques. The success rate for routine cataract surgery following radiation therapy is similar to that of the general population. In practice, the risk of cataract is not a limiting factor for delivering radiation therapy, neither in patients with a short life expectancy for whom there is a low probability of cataract occurrence (Rudoler et al., 1997b) , nor in patients with long life expectancy to whom surgery could be proposed if necessary. Radio-induced cataract remains rare as the sparing of the anterior chamber of the eye is often possible: physical restraints, physical field measurements and dosimetric studies are quite precise and allow control of the dose clinically delivered to the lens. In the study reported by Rudoler et al., 12% of the eyes developed significant complications after EBRT (28/233 eyes) with 30-40 Gy in 2-3 Gy fractions to the posterior or entire globe. The median follow-up for the entire cohort was 5.8 months (range: 0.7-170.0 months). Sixteen eyes developed cataracts, 6 eyes retinopathy, 5 eyes neuropathy, 5 eyes keratopathy, and 4 eyes iris neovascularization. Two eyes had narrow-angle glaucoma (one required enucleation). The authors concluded that the benefit of ocular EBRT for preservation of vision outweighed the risk of treatment complications (Rudoler et al., 1997a (Rudoler et al., , 1997b .
Outcomes.
EBRT for CM appears to yield good outcomes, although with a limited level of proof, as no randomized study against another treatment has been published and there are only two published prospective studies (Jardel et al., 2014) . Despite short followup due to limited survival associated with metastatic cancer, radiation therapy seems to be an effective treatment for CM (Table 8) . It is of note that clinical response to EBRT is often delayed (1-3 months or more) and the duration of improvement is of almost one year (Doig et al., 1992; Rosset et al., 1998; Röttinger et al., 1976) (Fig. 17) . In most cases, EBRT is performed after the initiation of a systemic therapy protocol (Fig. 18) . However, in some cases, especially when the primary cancer is not known at the time of CM diagnosis, EBRT can be performed prior to initiation of systemic treatment, possibly allowing for faster recovery of visual function (Fig. 19) .
Prescription 6.3.1.4.1. Timing of irradiation: pre-or post-chemotherapy?.
Performing irradiation before any systemic treatment allows to define precisely the target and to manage patients with rapid loss of vision. Treatment may also be concomitant: for known associations, such as gefitinib and irradiation in lung cancer, both treatments may be given at the same time without concerns for safely (Bhardwaj et al., 2016; Jiang et al., 2016; Zheng et al., 2016) ; if there is no data on the combination, the 5-half-life rule for drug washout is recommended. In cases of life threatening progressive extra-choroidal metastases without rapid loss of vision, systemic treatment with re-evaluation of the need for choroidal irradiation after 3 to 6 courses is recommended; if progressive disease occurs with rapid loss of vision, as the volume of irradiation is limited, the risk of toxicity should be reasonably low and may be worth taking.
EBRT planning.
Few authors have reported the details of radiotherapy treatment planning and EBRT technique. The patient's head is immobilized using a personalized thermoplastic mask. To ensure a reproducible lens position it is easiest for the eyes to be closed, which is normally associated with a downward gaze. However, for a better control of macular position the patient is asked to look straight ahead or to fixate a light in a defined position (Bellmann et al., 2000) . The metastasis, or gross tumor volume (GTV), is then identified on the dosimetric CT-scan as a mass attached to the posterior edge of Table 7 Organs at risk (OAR) in orbital radiation therapy. Standard fractionation = 1.8-2.0 Gy per fraction, 5 fractions per week.
Ocular tissues Dose objective (standard fractionation) Comments
Lens Mean lens dose < 0.5 Gy avoids lens opacities. Mean lens dose < 5-8 Gy avoids symptomatic cataract.
Acute lens toxicity is not seen. Radiation-induced cataract occurs generally 1-3 years after irradiation.
Cornea (Jeganathan et al., 2011) Maximal dose to cornea < 40-60 Gy avoid risk of keratitis, ulcer or edema. Perforation is rare and seen only above 60 Gy Acute toxicity is due to loss of the tea r film and generally resolves within a few weeks.
Retina (Emami et al., 1991; Parsons et al., 1994) Volume of retina receiving 45 Gy < 50% Acute retinal toxicity is not seen. Significant retinopathy occurred typically 3 months to 3 years after radiotherapy, depending on the dose and other medical condition (diabetes). Optic nerve (Bhandare et al., 2005; Parsons et al., 1994) Maximal dose to optic nerve < 55Gy Acute toxicity is not reported. Radiation-induced optic neuropathy occurs between 3 months and 8 years after treatment with a peak at 18 months. Chiasma (Bhandare et al., 2005; Parsons et al., 1994) Maximal dose to the chiasma < 55Gy Chiasma is posterior and generally preserved in the treatment of CM.
Table 8
The largest series of choroidal metastases treated by radiation therapy. EBRT: external beam radiotherapy; NR: Not reported.
T. Mathis et al. Progress in Retinal and Eye Research 68 (2019) 144-176 the eyeball; planar fundus images are used when available and a highresolution MRI may be helpful for better delineation of the volumes using image fusion. The clinical target volume (CTV) includes probabilistic areas of microscopic invasion next to the GTV; five millimeter expansions are applied around the GTV to create a CTV (Bellmann et al., 2000) . Once the CTV is determined, a supplementary circumferential margin of 3-5 mm is applied to offset positional and physical uncertainties (planning target volume, PTV). Organs at risk are then delineated. Field geometry varies greatly in the literature and tumor targeting may be achieved using one or two beams, laterally or with non-coplanar oblique beams. The ultimate goal is to deliver at least 95% and up to 100% of the total dose to the target while the organs at risk receive the minimal achievable dose. The simplest field arrangement for a unilateral treatment could be a lateral 6 MV photon field (inclined and edged to avoid the lens); possibly together with a smaller dose to the anterior field for better dose homogeneity (Fig. 20) . A recent advance in EBRT for the treatment of CM is IMRT. Five to nine fields are used (instead of 1-3 with 3D EBRT) and modulated with a multileaf collimator. Complex concave dose distributions can be achieved, which may be better shaped in the high-dose regions, despite some low-dose spillage to the anterior chamber. The treatment planning process of IMRT is more complex and its use is usually limited to extended posterior pole metastases in patients with relatively good general prognosis. 6.3.1.4.3. Target. Pre-treatment evaluation. For conventional 3D EBRT and SBRT, routine ophthalmological exams and visual evaluation are sufficient to diagnose the CM and to plan treatment. The aim is to not needlessly delay the treatment. Histological proof is not required, unless there is an atypical clinical presentation. A brain MRI is nonetheless required to eliminate synchronous brain metastases. A. Retinophotography at baseline. Initial visual acuity was 0.6 in right eye and 1.0 in left eye; B. Retinophotography 6 months after EBRT at 30 Gray showing atrophic changes after therapy that appears larger than the choroidal metastases. Visual acuity remained stable in both eyes with final acuity at 0.6 in right eye and 1.0 in left eye. T. Mathis et al. Progress in Retinal and Eye Research 68 (2019) 144-176 Bilaterality. The risk of bilateral CM is well documented (see section 4.1.2). Bilateral CM can be synchronous or metachronous, symptomatic or not. Including the contralateral posterior orbital cone in a target volume is controversial. Some recommend unilateral treatment, arguing that the exit dose using a lateral beam is sufficient to eradicate microscopic disease (i.e. the fraction of dose received by the other eye due to its proximity and dose distribution with EBRT using photons). For instance, in the German study ARO 95-08, none of the patients with unilateral CM irradiated with a unilateral field developed contralateral metastasis during a median follow-up of 5.8 months . However, this study was conducted in the 90's and less advanced irradiation techniques and conformation may have resulted in a higher dose delivery to the contralateral eye. Others recommend bilateral fields (Rosset et al., 1998; Wiegel et al., 1999) , but there is no strong evidence to support prophylactic irradiation of an eye showing no sign of CM at baseline. The complexity of treating the second eye at a later date is also dependent on the initial dose received.
Risk of synchronous or metachronous brain metastases. About two-thirds of patients with CM have extra-ocular metastases (Jardel et al., 2014) . A high incidence of central nervous system involvement was reported in breast and lung cancer patients with CM: 32% of synchronous brain metastases in the series reported by Kreusel et al. (pa- tients with lung cancer) and by Amer et al. (62% of patients with breast cancer) (Amer et al., 2004; Kreusel et al., 2008) . MRI is thus recommended to look for concomitant brain metastases, the presence of which is technically challenging because there may be overlaps (and overdose, which may be associated with radiation-induced toxicity) between radiation fields for CM and brain metastases. For instance, when EBRT is performed for brain metastases or brain prophylaxis, the posterior orbits receive a significant dose of radiation which has to be taken into account to minimize the risk of radiation-induced complications, especially on the central nervous system and optic nerves. Conversely, in case of isolated CM, the fields have to be carefully chosen to avoid overlapping with the brain, as whole-brain irradiation may be needed at a later date. In case of synchronous and symptomatic brain metastases, whole brain irradiation is indicated, and it will encompass the posterior orbits and choroids. EBRT is rapidly delivered, during the time needed to organize chemotherapy (radiation therapy is given during 5-10 consecutive working days). This is the best way to obtain a strong and rapid response on neurological symptoms as T. Mathis et al. Progress in Retinal and Eye Research 68 (2019) 144-176 systemic treatments might be too slow, hindered by the blood-brain barrier. Moreover, radiotherapy decreases the risk of developing other brain metastases.
EBRT dose and fractionation.
In the largest published series to date, Rudoler et al. reported outcomes from 233 eyes irradiated for posterior uveal metastases. The majority (72%) of patients received total doses between 30 and 40 Gy in 2-3 Gy fractions corresponding to a biologically effective dose between 50 and 70 Gy (Rudoler et al., 1997b) . Another study reported by Demirci et al. described a series of patients treated by 20-64 Gy in 8-32 fractions (Demirci et al., 2003) . However, short hypofractionated palliative courses are often preferred for patients with short life expectancy; the most common regimens are 30 Gy in 10 fractions, or 20 Gy in 5 fractions. For those with a life expectancy greater than one year, a normofractionated scheme could be considered in order to minimize the long-term side effects. Moreover, when OCT confirms involvement of the subfoveolar region, a more conservative approach using a normofractionated scheme is justified and should be considered.
6.3.1.4.5. In case of choroidal metastasis relapse. When CM relapses after initial radiation therapy, re-irradiation may not be possible owing to dose limiting constraints for sensitive ocular tissues irradiated during the initial treatment. There is a lack of data for ocular re-irradiation, but as is the case for other organs, target volumes are usually limited to the recurrent GTV and careful evaluation of the risk-benefit ratio should be carried out (Mbeutcha et al., 2017) ; in CM, PBT, SBRT, or plaque brachytherapy may be used as they allow the delivery of a high dose in a smaller target volume with better sparing of surrounding tissues.
Stereotactic irradiation
The principle of stereotactic irradiation is to deliver a high dose of radiation in a small tumor volume in a single fraction (radiosurgery) or a few fractions (hypofractionated stereotactic irradiation). It can be used as an alternative to PBT in unifocal CM, and is becoming widely available although it requires long treatment times and eye tracking capabilities, unless ocular immobilization is performed. Bellman et al. published a series of 10 patients treated for CM by stereotactic radiosurgery (12-20 Gy in one fraction) and long-term tumor control was achieved using shorter treatment course than with conventional EBRT. During follow-up (median: 26 months, range: 4-144 weeks) tumor regression was noted on ultrasound or MRI in 5/10 patients but only 4/10 patients had stabilization or improvement of their vision; no chronic side-effect was observed (Bellmann et al., 2000) . A Korean study analyzed 7 cases of CM treated by Gamma Knife radiosurgery with a single dose (median: 20 Gy, range: 15-25Gy). Median follow-up was 8 months. Five patients had lung cancer; the other two had gastric and renal cell cancer. Interestingly, four patients had multiple brain metastases that were treated simultaneously with radiotherapy (SBRT or EBRT). Two patients even received repeated SBRT after the first treatment for new intracranial lesions. Six patients had visual improvement after treatment; five CM disappeared completely on MRI. No acute complication attributable to the treatment itself was reported (Cho et al., 2018) .
Several limitations are encountered with SBRT. It is minimally invasive but it implies complete immobilization of the eye to reduce the intra-and inter-fraction movements, thus reducing the volume to treat. This is made difficult by the length of the treatment session (always greater than 30 min) which requires perfect patient cooperation. For instance, in the study reported by Cho et al., anesthetic ocular blocks and bridle suture were performed (Cho et al., 2018) . The technique may not be applicable in patients with severe loss of vision as eye fixation is not possible. Taken together, stereotactic irradiation is feasible for CM treatment but its value has to be evaluated in larger series and it may require invasive eye fixation tools.
Proton beam therapy
PBT is another radiotherapy technique that is effective in treating choroidal melanomas (Caujolle et al., 2010; Damato et al., 2005; Gragoudas et al., 1982) . In the treatment of CM, it is usually reserved for patients with long life expectancy and relatively radioresistant tumors (sarcomas, melanomas, kidney carcinomas) or unifocal tumors. Due to the physical properties of protons, the energy is delivered with a sharp final peak known as the Bragg peak. This allows a very focused and high-dose volume with preservation of surrounding tissues. Ocular PBT is performed in a limited number of centers, although numerous construction projects are underway worldwide. Tsina et al. published a series of 63 patients with CM treated by PBT (Tsina et al., 2005) ; they received 2 fractions of 14 Gy corrected for the relative biologic effectiveness of protons compared to photons (Gy_ RBE ). Eighty-four percent of treated tumors regressed completely within 5 months of treatment and there was no case of recurrence during follow-up (mean: 10 months). Complications occurred in 56% of cases and included minor and major adverse effects: dermatitis (17%); madarosis (28%), dry eye syndrome (6%) keratitis (8%), cataract (11%), neovascular glaucoma (8%), maculopathy (19%), chorioretinal atrophy (3%), and papillopathy and optic atrophy (22%). Similarly, Kamran et al. described a retrospective cohort of 77 patients with CM mostly treated with 2 fractions of 10 Gy; median follow-up was 7.7 months and local control was achieved in 94% of patients. Treatment-related adverse effects were reported in 31% of patients and visual acuity improved or was stable in 38% of eyes treated (Kamran et al., 2014) .
The main drawback of PBT as proposed in these series is the limited potential for macular sparing for tumors mainly located in the posterior pole. For patients with tumors next to the macula, PBT may be best performed in smaller doses per fraction that can be achieved by fractionated PBT, and helps spare normal tissues that are more easily damaged by high doses per fraction (Fig. 21) . However, the procedure may last 10 seconds to more than 2 minutes therefore requiring ocular gating or tracking. The use of fiducials ensures proper positioning of the eye before beam delivery; these are best placed around the metastasis to target the proton beam and better preserve sensitive tissues. Furthermore, an ocular gating system based on an infrared camera is used allowing immediate interruption of the proton beam in case of gaze deviation.
Overall, PBT should be considered in cases of peripheral or radioresistant tumors, but additional studies are required. It is of note that the great majority of published data on ocular treatments concerns passive, single scattering proton therapy with dedicated eyelines. There is very limited experience in ocular treatments with active, pencil beam scanning, or PBT using high energy equipment. Most centers are not properly equipped (from a technical and physical standpoint) to perform ocular treatments. However, beam quality, as reflected by dose gradient and sharpness in the Bragg peak area is expected to be lower with pencil beam scanning than with passive scattering. Similar to SBRT, such techniques are encouraging in selected patients who have oligometastatic radioresistant disease with relatively good prognosis for whom visual preservation is an important objective.
Plaque brachytherapy
The principle of plaque brachytherapy is to apply a radioactive isotope to the sclera that will deliver radiation over a short distance to the target tissue. It basically requires suturing a radioactive plaque onto the sclera, above the tumor. The plaque remains in place until the therapeutic dose is fully delivered (2-4 days). The patient can return home after surgical removal of the plaque to avoid radiation risk to others (Bell and Wilson, 2004; Lim and Petrovich, 2000) . The first reports were published in the 1930s for the treatment of malignant tumors of the eye (Moore, 1930) . A thin piece of metal (usually gold) is used, with radioactive seeds placed on one side. The dose distribution varies depending on the chosen isotope , which have various profiles of radiation emission) and the way the metallic plaque is manufactured and shaped (Chiu-Tsao et al., 2012).
The most widely used isotope is Iodine-125, which allows sparing of the adjacent tissues such as the lens and the retina due to its low energy photon-emitting profile (Shields, 1998) . It also enables a safe surgical procedure as its radioactivity can be contained on a gold sheet a mere 0.5 mm thick (Earle et al., 1987; Echegaray et al., 2017; Rotman et al., 1977) . It may be used in select cases of CM such as solitary and well delineated anterior tumors. Indeed, while EBRT delivers a uniform dose to the whole eye structure, plaque brachytherapy delivers a much more heterogeneous dose from the sclera to the apex of the tumor. Shields et al. treated the largest series of patients (36 individuals) with CM by iodine-125 plaque brachytherapy. The mean treatment time was 86 h, and the mean therapeutic dose was 68.80 Gy (45-70 Gy) to the tumor apex and 235.64 Gy to the tumor base. All tumors regressed, and a complete response was found in 94% of cases. The metastases flattened while the exudative signs resolved. Recurrence occurred in only 2 cases over a mean follow-up period of 11 months. The overall complication rate was low, and included radiation retinopathy, optic neuropathy and cataract .
Fifteen other studies are presented in Table 9 . An objective response was achieved in most cases, generally within the first 3 months after treatment (C. L. Shields et al., 1995b; Shields et al., 1997a) . Iodine-125 brachytherapy was used in most cases, with anecdotal use of . It must be noted that a third of these patients had undergone EBRT and/or systemic chemotherapy beforehand. Only four studies reported radiation complications such as optic atrophy, radiation retinopathy, or cataract and iris neovascularization. This low complication rate might be due to the rather short life expectancy of metastatic patients. Overall, plaque radiotherapy can be considered as a more rapid alternative to EBRT, even if this irradiation technique remains invasive . However, it is only available in some specialized radiation oncology departments.
Local treatment performed by ophthalmologists
The goal in emerging "office-based" local therapies is to restore visual function while minimizing ocular toxicity, here defined as collateral damage to other parts of the eye. When metastatic patients have a short life expectancy, quality of life is preferred over the chance of remission, and conservative treatments which are able to preserve vision are required. Moreover, autonomy and improvement of quality of life are key goals in the management of ocular metastases.
Photodynamic therapy
Photodynamic therapy (PDT) is a minimally invasive treatment in which a nontoxic light-sensitive compound (photosensitizer) is administered and subsequently activated by light exposure. The photosensitive molecules accumulate in the target tissue and their activation produces photochemical effects in the tissue. Thus, PDT combines the benefits of a preferential concentration of the photosensitizer in a definite area and the specific activation by light irradiation (Moan and Berg, 1992) .
PDT is currently used to treat solid tumors and is approved by the Food and Drug Administration in the treatment of skin, esophageal, and non-small cell lung cancer. In ophthalmology, PDT is known to treat, with limited side-effects, choroidal lesions including choroidal neovascularization, choroidal hemangiomas, and chronic central serous chorioretinopathy (Newman, 2016) .
While many photosensitizers are used in oncology, verteporfin (benzoporphyrin derivative monoacid ring A, BPD-MA) is the most used in ophthalmology. Verteporfin is a lipophilic photosensitizer and is more easily taken up by activated cells such as malignant cells (Allison et al., 1994; Jamieson et al., 1990) . Verteporfin is administered intravenously in a liposomal form. In the circulation, liposomal verteporfin (LV) binds to low density lipoprotein (LDL) with a strong affinity (Allison et al., 1990) and it is known that tumor tissue and cells have a higher number of LDL receptors than normal cells (Ho et al., 1978; Vitols et al., 1984) and a higher vascular permeability (Roberts and Hasan, 1992) . Although there is limited published data regarding LV-LDL vectorization to human tumor tissue, in mice the administration of BPD premixed with LDL resulted in enhanced delivery to the tumor area and increased photosensitization compared with BPD administered in an aqueous solution (Allison et al., 1991; Schmidt-Erfurth et al., 1997) . Moreover, LV is also selectively taken up by neovascular endothelium in mice (Roberts and Hasan, 1992) . In summary, the mechanism for specific accumulation of verteporfin in tumors may be explained as follows: building of a complex with LV and LDL in the circulation, vectorization of the LV-LDL to the targeted tumor cell and adjacent neovascularization, and selective delivery and accumulation of the photosensitizer to the tumor by LDL receptor -mediated endocytosis (Fig. 22) . T. Mathis et al. Progress in Retinal and Eye Research 68 (2019) 144-176 Breast (11) Lung (2) Prostate (2) Gastrointestinal (2) Thyroid (1) Kidney (1) Skin melanoma (2) Unknown (5) 35%:
EBRT (6) CT ( Regression (1) NR (1) papillopathy and retinopathy ( Breast (5) Pancreas (1) EBRT (1) NR I-125 (4) Increased (2) Stable (1) Decreased (3) 3.6/10
Regression ( T. Mathis et al. Progress in Retinal and Eye Research 68 (2019) 144-176 Exposure to light then leads to activation of the photosensitizer, which produces reactive oxygen species (ROS) in the tissue microenvironment. There are 3 mechanisms of action for these ROS: direct tumor cytotoxic effect leading to cell death predominantly by apoptosis and necrosis (Dougherty et al., 1998) ; intraluminal thrombosis and destruction of peritumoral vasculature (Fingar et al., 1999) ; local inflammatory reaction resulting in increased autophagy. In the latter case, PDT induces an acute inflammation at the target site secondary to oxidative stress (Dougherty et al., 1998) . The production of ROS and tumor cell death is accompanied by activation of the complement pathway and secretion of inflammatory cytokines. This leads to the recruitment of macrophages and dendritic cells, and the phagocytosis of tumor cell debris. Dendritic cells migrate to the local lymph nodes and differentiate into professional antigen-presenting cells. Tumor antigen presentation within the lymph nodes is followed by clonal expansion of tumor-sensitized lymphocytes that home to the tumor and eliminate residual tumor cells (Agostinis et al., 2011) .
Harbour et al. were the first to report the use of PDT for the treatment of CM in a patient with persistent ocular symptoms despite both chemotherapy and ocular EBRT in a context of pulmonary carcinoid tumor (Harbour, 2004) . Few authors have subsequently reported cases of different types of primary tumor (Isola et al., 2006; Kaliki et al., 2012; Kawakami et al., 2013; Mauget-Faÿsse et al., 2006; Soucek and Cihelkova, 2006) . Ghodasra et al. treated 21 tumors in 13 eyes of 10 patients that led to 81% of total tumor resorption despite 70% systemic cancer progression in these patients (Ghodasra and Demirci, 2016) . These data suggest that PDT provides reasonable rates of tumor regression with good safety (Ghodasra and Demirci, 2016; Kaliki et al., 2012) . Multiple sessions of PDT may be necessary and well tolerated in cases of recurrence or inefficacy, suggesting that PDT is still effective Fig. 22 . Mechanism of action of PDT. After intravenous injection of verteporfin and building of the complex with LDL (LV-LDL) (1), verteporfin molecules accumulate in the tumor through LDL receptors (LDL Rc) (2). Then a 689 nm light exposition (3) on the tumor bed leads to activation of the molecules of verteporfin, producing reactive oxygen species (ROS) (4). while systemic treatment may not be (Ghodasra and Demirci, 2016; Kaliki et al., 2012; Soucek and Cihelkova, 2006) (Fig. 23) . Systematic analysis of the published literature on the treatment of CM by PDT as a first or second line of treatment suggests treating selected patients with one or two CM (Table 10) . PDT seems to be more effective in treating retro-equatorial tumor with low to moderate exudative symptoms, and with a thickness less than 3 mm and diameter less than 10 mm. Lesions that are too thick might not be eligible for PDT, since the wavelength (689 nm) of the laser used will not penetrate the entire tumor. Moreover, visual acuity seems to improve after PDT probably due to the decrease of SRF.
Despite these promising results, there are reports of PDT failures. Hua et al. describe the case of a patient with a 4.2 mm-thick CM of a lung cancer who received PDT treatment with no concomitant chemotherapy. Multimodal imaging at 3 weeks follow-up found an increase in tumor size and exudative signs. Systemic evaluation showed progression of the metastatic disease. Ghodasra et al. also described the failure of PDT treatment in one of ten patients with aggressive multi metastatic disease who did not receive any previous or concomitant chemotherapy (Ghodasra and Demirci, 2016) . However, these failures might be explained by the large tumor size, the short duration of followup, the lack of adjuvant chemotherapy or the aggressive multimetastatic status of the patient.
The overall clinical effectiveness is rather promising, especially for patients who often have short survival rates and might be looking for time-sparing treatments. While EBRT takes weeks to treat ocular tumor, PDT allows treatment in a single day, which is desirable for the quality of life of these patients with limited survival. Furthermore, contrary to PBT or plaque brachytherapy, this treatment avoids interventional surgery and potential side effects of irradiation.
PDT should be performed at full-fluence: intravenous verteporfin (6 mg/m2) is infused over 10 min. Five minutes later, a 689 nm diode laser is delivered to the area of the CM for 83 s at an intensity of 600 mW/ cm2 (50 J/cm2). If multiple spots are required, they must be overlapping to cover the whole diameter of the tumor. Furthermore, a 1 mm free margin may be treated around the tumor area.
Intravitreal injection
Another local treatment that could be performed by ophthalmologists alone is intravitreal injection (IVI) of anti-vascular endothelial growth factor (VEGF). The pathogenesis of CM begins with the hematogenous spread of the primary tumor. Once implanted in the choroidal space, tumor cells secrete neovascular factors allowing the supply of nutrients and oxygen necessary for proliferation (Langley and Fidler, 2011) . These are initially supplied from the host vascular system, but the demand soon exceeds the supply from this source, and therefore tumors develop their own functional vascular supply (Folkman, 1986 ) from the normal host vascular network by the process of angiogenesis (Bergers and Benjamin, 2003) . Pathological angiogenesis is not auto-regulated and results from alterations in growth control. The induction of angiogenesis has been shown to correlate with the invasive properties of tumors and is associated with poor prognosis (Nishida et al., 2006) .
VEGF is an angiogenic agent that increases vessel permeability and enhances endothelial cell growth, proliferation, migration, and differentiation (Johnstone and Logan, 2007) . VEGF also promotes angiogenesis in different tumor types and may affect tumor growth, metastatic potential, and response to radiotherapy (Nishida et al., 2006) . VEGF expression may prove to be an important prognostic factor in head and neck cancer as VEGF positivity is the most significant predictor of poor prognosis (Smith et al., 2000) . Angiogenic factors and isoforms of VEGF were found to be over-expressed in choroidal melanoma (Boyd et al., 2002) .
CM are not exempt of these rules and have been shown to have hypervascularity (Neudorfer et al., 2011) . As primary tumor and CM growth seems to be strongly dependent on angiogenesis and VEGF, one can imagine that anti-VEGF therapy could lead to a reduction in tumor mass and exudation.
From a pharmacological standpoint, it is not clear how the anti-VEGF injected in the vitreous is able to reach the choroid that is protected by the outer blood-retinal barrier (see 6.2.1). Some investigations on anti-VEGF clearance have shown that bevacizumab permeates through the blood-retinal barrier and is found in the choroid (Heiduschka et al., 2007; Shahar et al., 2006; Stewart, 2014) . Although mechanisms of barrier breakdown are still unknown, it is suspected that RPE alterations caused by the underlying choroidal tumor, which are clearly visible on FA, may lead to blood-retinal barrier disruption, facilitating drug access to the choroid.
The very first reports of intravitreal anti-VEGF use in CM found dramatic improvement; three out of 4 cases showed a nearly complete regression of the CM, and huge improvement in visual acuity a few months after the first injection (Kim et T. Mathis et al. Progress in Retinal and Eye Research 68 (2019) 144-176 et al., 2010) . Many authors have since reported cases of successful management of CM from various primary locations with systemic (George et al., 2009; Kourie et al., 2015) or intravitreal anti-VEGF (Table 11) . Intravitreal anti-VEGF shows promising results, regarding both clinical outcome and quality of life of patients, as it is by far less invasive than conventional chemotherapy or radiation therapy. Combined with systemic chemotherapy, it allowed local control of the CM in most cases, often leading to complete regression of both tumor and exudative retinal detachment. Interestingly, FA after IVI shows a marked reduction of vascularity and leakage in the tumor bed, suggesting an antiangiogenic and antipermeability effect on the tumor neovessels (Kim et al., 2009; Kuo et al., 2008; Mansour and Alameddine, 2012) . Several IVI are sometimes needed to treat the tumor and an asneeded regimen is used in this case. It should be noted that most of the patients treated by IVI were receiving systemic chemotherapy before or during intraocular treatment and therefore the true effectiveness of IVI may have been overestimated. However, in most patients, the immediate effect observed after IVI should be attributed to the intravitreal anti-VEGF and it can be effective even in cases refractory to conventional treatment (Lai et al., 2012; Yao et al., 2010) . This therapy could also be proposed in association with other local treatments to hasten fluid resorption and thus improve functional results. However, some failures have also been reported (Boss et al., 2016; Lin et al., 2010; Maturu et al., 2014; Maudgil et al., 2015) ; for these cases, systemic therapies were generally not given at the time of IVI or failed to control other metastases.
Overall, IVI treatment might be a good therapeutic option for patients with a metastatic disease as it preserves the quality of life without reducing clinical effectiveness. Clear guidelines concerning the use of IVI are still to be determined. It may be suggested to begin with a single dose followed by a monthly as-needed regimen. Conversely to other local treatments, IVI has a very low rate of side effects, including the risk of endophthalmitis which, for this treatment, is about 1 in 2000 patients (Benoist d'Azy et al., 2016; Fileta et al., 2014) ; it could be proposed to multi-metastatic patients under systemic chemotherapy with short life expectancy, as it improves or preserves the vision in most cases without time-consuming treatment. Furthermore, unlike PDT, this treatment can be given in cases of exudative or large tumors.
Decisional trees in a multimodal approach of choroidal metastases
When dealing with a CM, several points should be raised: are the CM responsible for ocular symptoms; how long is the patient's life expectancy; are there other metastases, are they life-threatening, and how should multimodal treatment be managed?
Most patients with CM have systemic molecular treatment for their primary tumor or metastatic spread. Patients with specific oncogenic driver mutations or translations may exhibit dramatic tumor response under specific targeted therapies, including a decrease in tumor mass and exudative syndrome (Demirci et al., 2003; Manquez et al., 2006; Shah et al., 2014; Yang et al., 2014) . However, secondary resistance to systemic treatment is common and may ultimately be associated with treatment failure after initial (transient) tumor response (Cui et al., 2017; Okuma et al., 2015) . Therefore, it makes sense to propose local treatment concomitantly or after systemic therapy to provide a more sustainable response. Depending on the life expectancy, the number of CM, and their localization different approaches can be proposed to the patient, and these are described below. (Fig. 24) When life expectancy is considered long, a more effective and durable response to treatment of the CM is preferred. The patient may be willing to undergo a multimodal treatment with numerous appointments (EBRT) or requiring eye surgery (PBT, Brachytherapy) .
In cases of long life expectancy
In case of multiple and disseminated CM foci, and/or when bilateral CM metastases are present, EBRT is considered upfront. When the metastasis is unilateral and unique, a more localized treatment, such as PBT, plaque brachytherapy or SBRT should be considered as an alternative to conventional EBRT. Although PBT and plaque brachytherapy provide similar results for the majority of ocular tumors, plaque brachytherapy is less frequently used for tumors posterior to the equator due to the intra-operative accessibility, or in cases of large tumor diameter. More studies are needed to evaluate the effectiveness of SBRT and to define the place of this technique as ocular immobilization remains the main obstacle for its use. PBT is the treatment of choice for radioresistant tumors as the proton beam provides a high-dose volume with sharp dose deposition allowing the preservation of surrounding tissues. When the CM is very close to the macula, there is a risk for visual deterioration, but tumor control may be privileged in case of unilateral CM. It should be performed after fiducial implantation at the surface of the sclera to define tumor borders and for stereotactic modeling of eye orientation. When the CM is near the macula or the optic disc area and primary cancer is relatively radiosensitive, EBRT may be preferred. PDT could be an alternative, but patients should be followed carefully due to the risk of relapse.
There are no guidelines for the treatment of asymptomatic CM; management depends on the area involved by the tumor. In case of asymptomatic lesions located in critical areas, such as the macula and optic disc, the risk for iatrogenic complications from irradiation may outweigh the risk for vision loss in the short term. In such tumors, strict follow-up may help to determine whether the lesion is rapidly progressive or stable. If it is progressive, irradiation using a conservative approach may be recommended, such as normofractionated EBRT or PDT. If the lesion is stable, continued observation may be recommended provided that the patient is compliant to medical visits. In case of asymptomatic lesions located outside critical areas, a strict follow-up is recommended. In case of progression, high-dose irradiation may be used safely. (Fig. 25) Local treatment in such cases should be carefully discussed with the patient and the oncologist. The priority is to maintain the quality of life, and this may include, for some patients, retaining some vision for the end of their life. When a treatment is proposed for a palliative-care patient, it should include minimal time spent in a medical setting and should avoid redundant consultations. If systemic therapy fails to sustain sufficient vision, local treatment could be proposed. It should be prompt and effective to allow rapid vision gain.
In cases of short life expectancy
When patients have synchronous cerebral metastases requiring brain EBRT, the choroids can be treated at the same time. In case of unilateral and unique CM, PDT and/or anti-VEGF IVI is proposed, knowing that PDT leads to poorer results if exudation is intense or in large and thick tumors as the laser beam does not penetrate as well. Follow-up of patients treated by anti-VEGF IVI should be regular because some failures are reported, especially in the absence of systemic therapy. A combined treatment with a few anti-VEGF IVI followed by PDT could be proposed to patients with a highly exudative lesion. In cases of multiple or bilateral CM, a short palliative hypofractionated EBRT is proposed; if there are a few unilateral CM, anti-VEGF IVI and/ or PDT can be considered.
Conclusion and future direction
Enhanced imaging of the retina and choroid allows a better understanding and precise diagnosis of CM, even before they are visible on fundus. This diagnosis is most often made using clinical findings in the context of a known cancer, with or without known metastases. However, up to a third of patients have no history of cancer at the time of CM diagnosis, and ocular manifestations are the first sign of systemic disease. Therefore, ophthalmologists must be familiar with the Table 11 Studies using intravitreal injection (IVI) of Bevacizumab (except one with Ranibizumab) for treatment of choroidal metastases. (2) Lung (1) PDT (1) EBRT (1) None ( T. Mathis et al. Progress in Retinal and Eye Research 68 (2019) 144-176 diagnostic features and general work up of CM, allowing prompt treatment of the primary cancer. When work-up fails to identify the primary cancer, choroidal tumor biopsy or liquid biopsy can help speed up the diagnosis. This is especially important since emerging targeted treatments have greatly improved survival in the past decade. Several therapeutic options are available, but randomized studies comparing different approaches are still needed to guide optimized treatment schemes depending on cancer phenotypes and general status of the patient. In this review, we provide an overview of the treatment options available, their advantages and their limits. The common objectives of all treatments are to preserve or improve vision, avoid enucleation, and maintain quality of life.
To date, radiotherapy remains the treatment of choice for CM: there is longstanding experience and good results are reported in the literature. It may be performed alone for solitary tumors located in the eye only, or it can be associated with systemic treatment in case of disseminated metastatic disease. Fractionated conventional lens sparing techniques can be considered as a gold standard. In selected patients, Fig. 24 . Decision tree in case of long life expectancy. In addition to treatment for choroidal metastases, systemic therapy is recommended if there are other extrachoroidal metastases. * Proton beam therapy (PBT) should be performed after fiducial placement to ensure the correct positioning of the eye. IVI: intravitreal injection; PDT: photodynamic therapy; EBRT: photon-based external beam radiotherapy; SBRT: stereotactic beam radiotherapy. T. Mathis et al. Progress in Retinal and Eye Research 68 (2019) 144-176 local irradiation techniques used to treat primary eye tumors may be considered for the management of CM, such as plaque brachytherapy, PBT, or optimized photon-based techniques. Other local treatments, such as PDT or intravitreal anti-VEGF, are available and can decrease the need for radiation and its side effects, and reduce time spent in medical settings for multimetastatic patients. The effectiveness of systemic therapies, especially targeted agents, should be assessed more specifically, and their place in the treatment strategy should be discussed in future recommendations. Further identification of biomarkers is needed to unravel disease mechanisms and to tailor management of CM to the individual.
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